These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 2653884)
1. [Correction of the level of peptide leukotrienes as mediators of ischemia and shock]. Kotsiuruba VN; Moĭbenko AA Fiziol Zh (1978); 1989; 35(1):94-103. PubMed ID: 2653884 [TBL] [Abstract][Full Text] [Related]
2. Thromboxane A2 and leukotrienes are eicosanoid mediators of shock and ischemic disorders. Lefer AM Prog Clin Biol Res; 1988; 264():101-14. PubMed ID: 2837782 [TBL] [Abstract][Full Text] [Related]
3. [Leukotrienes as mediators in the pathogenesis of shock]. Guhlmann A; Keppler D Verh Dtsch Ges Inn Med; 1990; 96():693-6. PubMed ID: 2092507 [No Abstract] [Full Text] [Related]
4. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Chen XS; Sheller JR; Johnson EN; Funk CD Nature; 1994 Nov; 372(6502):179-82. PubMed ID: 7969451 [TBL] [Abstract][Full Text] [Related]
5. [Leukotrienes--mediators of inflammation, ischemia and shock. Their significance in the pathogenesis of central nervous system diseases]. Mayer M Cas Lek Cesk; 1987 Jan; 126(1):15-8. PubMed ID: 3026632 [No Abstract] [Full Text] [Related]
6. Leukotrienes and other lipoxygenase metabolites of arachidonic acid: their role in edema, ischemia and demyelination of the central nervous system. Mayer M Acta Univ Palacki Olomuc Fac Med; 1988; 119():181-6. PubMed ID: 2977480 [No Abstract] [Full Text] [Related]
7. Eicosanoids as mediators of ischemia and shock. Lefer AM Fed Proc; 1985 Feb; 44(2):275-80. PubMed ID: 2981745 [TBL] [Abstract][Full Text] [Related]
8. [Novel findings from an animal tourniquet shock model]. Hiraiwa K Nihon Hoigaku Zasshi; 2003 Sep; 57(2):125-34. PubMed ID: 14574964 [TBL] [Abstract][Full Text] [Related]
9. [Physiopathology of asthma: what role for leukotrienes?]. Lockhart A; Dinh-Xuan AT Rev Pneumol Clin; 1997; 53(3):119-27. PubMed ID: 9296112 [TBL] [Abstract][Full Text] [Related]
10. Cellular alterations in shock and ischemia and their correction. Chaudry IH Physiologist; 1985 Apr; 28(2):109-18. PubMed ID: 4001176 [No Abstract] [Full Text] [Related]
11. [Effect of hypoxia on nitric oxide formation and leukotriene metabolism in the perfused rat liver]. Wettstein M; Häussinger D Zentralbl Chir; 1994; 119(5):328-33. PubMed ID: 7517604 [TBL] [Abstract][Full Text] [Related]
12. [The significance of leukotrienes in pathophysiology of bronchial asthma--therapy perspectives]. Wojnowski P; Patkowski J Postepy Hig Med Dosw; 1997; 51(5):499-514. PubMed ID: 9489451 [TBL] [Abstract][Full Text] [Related]
13. Prostaglandins, thromboxanes, leukotrienes, and cytochrome P-450 metabolites of arachidonic acid. Cook JA; Geisel J; Halushka PV; Reines HD New Horiz; 1993 Feb; 1(1):60-9. PubMed ID: 7922394 [TBL] [Abstract][Full Text] [Related]
14. The role of lipid mediators in asthma (current views and perspectives). König W; Schönfeld W; Knöller J; Köller M Allergol Immunopathol (Madr); 1988; 16(5):289-98. PubMed ID: 3147587 [TBL] [Abstract][Full Text] [Related]
15. [Leukotrienes in allergic inflammatory reactions]. Bogić M; Rasković S; Perić-Popadić A; Tomić-Spirić V; Andrejević S; Jovicić Z Srp Arh Celok Lek; 1998; 126(9-10):382-7. PubMed ID: 9863412 [TBL] [Abstract][Full Text] [Related]
16. The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues. Norel X; Brink C Pharmacol Ther; 2004 Jul; 103(1):81-94. PubMed ID: 15251228 [TBL] [Abstract][Full Text] [Related]
20. The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets? Sharma JN; Mohammed LA Inflammopharmacology; 2006 Mar; 14(1-2):10-6. PubMed ID: 16835707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]